alendronate has been researched along with Auricular Fibrillation in 14 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore the incidence of atrial fibrillation (AF) and other cardiovascular endpoints in clinical trials of alendronate." | 8.88 | Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. ( Barrett-Connor, E; Bone, HG; de Papp, A; Hustad, CM; Liberman, UA; Papapoulos, S; Santora, AC; Swern, AS; Wang, H, 2012) |
| "To explore the incidence of atrial fibrillation (AF) and other cardiovascular endpoints in clinical trials of alendronate." | 4.88 | Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. ( Barrett-Connor, E; Bone, HG; de Papp, A; Hustad, CM; Liberman, UA; Papapoulos, S; Santora, AC; Swern, AS; Wang, H, 2012) |
| "Alendronate sodium is used to reduce the risk of bone fracture in aged osteoporosis patients." | 3.96 | Transient increase in international normalized ratio (INR) and bleeding risk following Alendronate sodium in elderly patients on warfarin: Two case reports. ( Bian, P; Qian, S; Shi, L; Zhou, J, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (78.57) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Qian, S | 1 |
| Zhou, J | 1 |
| Bian, P | 1 |
| Shi, L | 1 |
| Strandberg, TE | 1 |
| Abrahamsen, B | 1 |
| Eiken, P | 1 |
| Brixen, K | 1 |
| Grosso, A | 1 |
| Douglas, I | 1 |
| Hingorani, A | 1 |
| MacAllister, R | 1 |
| Smeeth, L | 1 |
| Ringe, JD | 1 |
| Vestergaard, P | 1 |
| Schwartz, K | 1 |
| Pinholt, EM | 1 |
| Rejnmark, L | 1 |
| Mosekilde, L | 1 |
| Barrett-Connor, E | 1 |
| Swern, AS | 1 |
| Hustad, CM | 1 |
| Bone, HG | 1 |
| Liberman, UA | 1 |
| Papapoulos, S | 1 |
| Wang, H | 1 |
| de Papp, A | 1 |
| Santora, AC | 1 |
| Cummings, SR | 2 |
| Schwartz, AV | 1 |
| Black, DM | 1 |
| Karam, R | 1 |
| Camm, J | 1 |
| McClung, M | 1 |
| Zuber, MA | 1 |
| Lee, T | 1 |
| Cauley, JA | 1 |
| Ensrud, KE | 1 |
| Heckbert, SR | 1 |
| Li, G | 1 |
| Smith, NL | 1 |
| Psaty, BM | 1 |
1 review available for alendronate and Auricular Fibrillation
| Article | Year |
|---|---|
Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials.
Topics: Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Cardiovascular Diseases; Dose-Re | 2012 |
13 other studies available for alendronate and Auricular Fibrillation
| Article | Year |
|---|---|
Transient increase in international normalized ratio (INR) and bleeding risk following Alendronate sodium in elderly patients on warfarin: Two case reports.
Topics: Aged; Aged, 80 and over; Alendronate; Anticoagulants; Atrial Fibrillation; Bone Density Conservation | 2020 |
Alendronate, osteoporosis, and atherosclerosis.
Topics: Alendronate; Atherosclerosis; Atrial Fibrillation; Bone Density Conservation Agents; Humans; Osteopo | 2008 |
Atrial fibrillation in fracture patients treated with oral bisphosphonates.
Topics: Aged; Aged, 80 and over; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Case-Co | 2009 |
Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Atrial Fibrillation; Atrial Flutter; Bone Density Conservation | 2009 |
[Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
Topics: Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Clinical Trials as Topic; Diphos | 2009 |
Bisphosphonates and atrial fibrillation.
Topics: Aged; Alendronate; Atrial Fibrillation; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Ost | 2008 |
Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.
Topics: Aged; Alendronate; Atrial Fibrillation; Atrial Flutter; Bone Density Conservation Agents; Cohort Stu | 2010 |
Alendronate and atrial fibrillation.
Topics: Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Female; Fr | 2007 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diph | 2007 |
[Osteoporosis and bisphosphonates].
Topics: Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Dose-Respo | 2007 |
Ask the doctor. I am 86 years old and have been taking Fosamax to strengthen my bones for nearly 10 years. A few months ago, I suddenly fainted and was later diagnosed with atrial fibrillation. Did that happen because I was taking Fosamax?
Topics: Aged, 80 and over; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Humans; Osteo | 2007 |
Considering competing risks . . . Not all black and white.
Topics: Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Decision Making; Diabetes Mellit | 2008 |
Use of alendronate and risk of incident atrial fibrillation in women.
Topics: Aged; Aged, 80 and over; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Case-Co | 2008 |